Cargando…

Detection of EpCAM-Negative and Cytokeratin-Negative Circulating Tumor Cells in Peripheral Blood

Enrichment of rare circulating tumor cells (CTCs) in blood is typically achieved using antibodies to epithelial cell adhesion molecule (EpCAM), with detection using cytokeratin (CK) antibodies. However, EpCAM and CK are not expressed in some tumors and can be downregulated during epithelial-to-mesen...

Descripción completa

Detalles Bibliográficos
Autores principales: Mikolajczyk, Stephen D., Millar, Lisa S., Tsinberg, Pavel, Coutts, Stephen M., Zomorrodi, Maryam, Pham, Tam, Bischoff, Farideh Z., Pircher, Tony J.
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3090615/
https://www.ncbi.nlm.nih.gov/pubmed/21577258
http://dx.doi.org/10.1155/2011/252361
_version_ 1782203166230577152
author Mikolajczyk, Stephen D.
Millar, Lisa S.
Tsinberg, Pavel
Coutts, Stephen M.
Zomorrodi, Maryam
Pham, Tam
Bischoff, Farideh Z.
Pircher, Tony J.
author_facet Mikolajczyk, Stephen D.
Millar, Lisa S.
Tsinberg, Pavel
Coutts, Stephen M.
Zomorrodi, Maryam
Pham, Tam
Bischoff, Farideh Z.
Pircher, Tony J.
author_sort Mikolajczyk, Stephen D.
collection PubMed
description Enrichment of rare circulating tumor cells (CTCs) in blood is typically achieved using antibodies to epithelial cell adhesion molecule (EpCAM), with detection using cytokeratin (CK) antibodies. However, EpCAM and CK are not expressed in some tumors and can be downregulated during epithelial-to-mesenchymal transition. A micro-fluidic system, not limited to EpCAM or CK, was developed to use multiple antibodies for capture followed by detection using CEE-Enhanced (CE), a novel in situ staining method that fluorescently labels the capture antibodies bound to CTCs. Higher recovery of CTCs was demonstrated using antibody mixtures compared to anti-EpCAM. In addition, CK-positive breast cancer cells were found in 15 of 24 samples (63%; range 1–60 CTCs), while all samples contained additional CE-positive cells (range 1–41; median = 11; P = .02). Thus, antibody mixtures against a range of cell surface antigens enables capture of more CTCs than anti-EpCAM alone and CE staining enables the detection of CK-negative CTCs.
format Text
id pubmed-3090615
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-30906152011-05-16 Detection of EpCAM-Negative and Cytokeratin-Negative Circulating Tumor Cells in Peripheral Blood Mikolajczyk, Stephen D. Millar, Lisa S. Tsinberg, Pavel Coutts, Stephen M. Zomorrodi, Maryam Pham, Tam Bischoff, Farideh Z. Pircher, Tony J. J Oncol Research Article Enrichment of rare circulating tumor cells (CTCs) in blood is typically achieved using antibodies to epithelial cell adhesion molecule (EpCAM), with detection using cytokeratin (CK) antibodies. However, EpCAM and CK are not expressed in some tumors and can be downregulated during epithelial-to-mesenchymal transition. A micro-fluidic system, not limited to EpCAM or CK, was developed to use multiple antibodies for capture followed by detection using CEE-Enhanced (CE), a novel in situ staining method that fluorescently labels the capture antibodies bound to CTCs. Higher recovery of CTCs was demonstrated using antibody mixtures compared to anti-EpCAM. In addition, CK-positive breast cancer cells were found in 15 of 24 samples (63%; range 1–60 CTCs), while all samples contained additional CE-positive cells (range 1–41; median = 11; P = .02). Thus, antibody mixtures against a range of cell surface antigens enables capture of more CTCs than anti-EpCAM alone and CE staining enables the detection of CK-negative CTCs. Hindawi Publishing Corporation 2011 2011-04-19 /pmc/articles/PMC3090615/ /pubmed/21577258 http://dx.doi.org/10.1155/2011/252361 Text en Copyright © 2011 Stephen D. Mikolajczyk et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Mikolajczyk, Stephen D.
Millar, Lisa S.
Tsinberg, Pavel
Coutts, Stephen M.
Zomorrodi, Maryam
Pham, Tam
Bischoff, Farideh Z.
Pircher, Tony J.
Detection of EpCAM-Negative and Cytokeratin-Negative Circulating Tumor Cells in Peripheral Blood
title Detection of EpCAM-Negative and Cytokeratin-Negative Circulating Tumor Cells in Peripheral Blood
title_full Detection of EpCAM-Negative and Cytokeratin-Negative Circulating Tumor Cells in Peripheral Blood
title_fullStr Detection of EpCAM-Negative and Cytokeratin-Negative Circulating Tumor Cells in Peripheral Blood
title_full_unstemmed Detection of EpCAM-Negative and Cytokeratin-Negative Circulating Tumor Cells in Peripheral Blood
title_short Detection of EpCAM-Negative and Cytokeratin-Negative Circulating Tumor Cells in Peripheral Blood
title_sort detection of epcam-negative and cytokeratin-negative circulating tumor cells in peripheral blood
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3090615/
https://www.ncbi.nlm.nih.gov/pubmed/21577258
http://dx.doi.org/10.1155/2011/252361
work_keys_str_mv AT mikolajczykstephend detectionofepcamnegativeandcytokeratinnegativecirculatingtumorcellsinperipheralblood
AT millarlisas detectionofepcamnegativeandcytokeratinnegativecirculatingtumorcellsinperipheralblood
AT tsinbergpavel detectionofepcamnegativeandcytokeratinnegativecirculatingtumorcellsinperipheralblood
AT couttsstephenm detectionofepcamnegativeandcytokeratinnegativecirculatingtumorcellsinperipheralblood
AT zomorrodimaryam detectionofepcamnegativeandcytokeratinnegativecirculatingtumorcellsinperipheralblood
AT phamtam detectionofepcamnegativeandcytokeratinnegativecirculatingtumorcellsinperipheralblood
AT bischofffaridehz detectionofepcamnegativeandcytokeratinnegativecirculatingtumorcellsinperipheralblood
AT pirchertonyj detectionofepcamnegativeandcytokeratinnegativecirculatingtumorcellsinperipheralblood